Industry-Expert Theaters
Expo, #1957 and #2455

Connect with the experts in the Industry-Expert Theaters as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

Quick Links: SaturdaySundayMonday

Saturday, March 4

10:15 – 11:15 a.m.

4009. The Patient Journey – From Hospital, to Home, to Heart Recovery
Industry-Expert Theater 2, #2455
Sponsored by Abiomed

10:45 – 11:45 a.m.

4001. Title to be Announced
Industry-Expert Theater 1, #1957
Sponsored by Abbott

12:45 – 1:45 p.m.

4002. Elevated Lipoprotein(a): Raise Your Game and Lower Your (Risk) Score?
Industry-Expert Theater 1, #1957
Sponsored by Novartis Pharmaceuticals Corporation

4010. Title to be Announced
Industry-Expert Theater 2, #2455
Sponsored by Kiniksa Pharmaceuticals

3:15 – 4:15 p.m.

4003. ACC Recommends Lower LDL-C Thresholds For ASCVD Patients at Risk For CV Events
Industry-Expert Theater 1, #1957
Sponsored by Amgen

4011. Title to be Announced
Industry-Expert Theater 2, #2455
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

Sunday, March 5

9:15 – 10:15 a.m.

4004. Recognizing the Underrecognized: Transthyretin Cardiac Amyloidosis, a Potential Underlying Cause of Heart Failure
Industry-Expert Theater 1, #1957
Sponsored by Pfizer

Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious, underrecognized and underdiagnosed cause of heart failure. Early recognition of clinical clues and accurate diagnosis are crucial to starting patients on the appropriate continuum of care. Join us to help raise awareness of the signs and symptoms of ATTR-CM, and the role of cardiac health professionals in suspecting, diagnosing and confirming ATTR-CM. The program will end with a review of the clinical data supporting an oral treatment option for patients with this progressive disease.

4012. Is LEQVIO® (inclisiran) an Attractive Therapy? What Makes it Different?
Industry-Expert Theater 2, #2455
Sponsored by Novartis Pharmaceuticals Corporation

This program will discuss key aspects that make LEQVIO compelling and explore scenarios and considerations that make it well suited for patients with ASCVD with elevated LDL-C who may need something more, despite their best efforts with diet and maximally tolerated statin. Don't miss the deep dive into the mechanism of action, dosing schedule, administration, clinical efficacy, and safety data.

Jason Lecocq, MD, MBA
Senior Medical Director, Novartis Pharmaceuticals Corporation

11:15 a.m. – 12:15 p.m.

4005. Title to be Announced
Industry-Expert Theater 1, #1957
Sponsored by Amgen

4013. A Next Step in LDL-C–Lowering Therapy: Oral Nonstatin Therapies
Industry-Expert Theater 2, #2455
Sponsored by Esperion Therapeutics, Inc.

The session will cover the following information:

  • Atherosclerotic cardiovascular disease and lipid management
  • Unique mechanism of action for two treatment options
  • Efficacy data for two treatment options
  • Safety data for two treatment options
  • Overview of the ongoing Outcomes trial

Professor of Public Health and Honorary Consultant Cardiologist, President European Atherosclerosis Society, Imperial College London

3:30 – 4:30 p.m.

4006. Left Atrial Appendage Closure For Stroke Risk Reduction: New Data, New Insights
Industry-Expert Theater 1, #1957
Sponsored by Boston Scientific

  • Evolution of LAAC: Where are we now?
  • Anticoagulation and device-based therapies: stroke risk, bleed risk, and what matters to patients
  • What will happen with LAAC over the next decade? A peak into the future

4014. Transforming Hypertension Management With Ultrasound Renal Denervation
Industry-Expert Theater 2, #2455
Sponsored by ReCor Medical

Monday, March 6

9:45 – 10:45 a.m.

4007. Title to be Announced
Industry-Expert Theater 1, #1957
Sponsored by ZOLL

4015. Worsening Heart Failure in Patients With Symptomatic Chronic HFrEF: Will You Recognize the Early Downward Trajectory?
Industry-Expert Theater 2, #2455
Sponsored by Cytokinetics

During this presentation, we will review the downward trajectory of worsening heart failure in patients with symptomatic chronic HFrEF. We will discuss the burden of worsening heart failure and current treatment strategies. We will also explore the challenges posed by worsening signs or symptoms in high-risk patients, and share best practice considerations to identify early signs or symptoms.

Stephen J. Greenem, MD, FACC
Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute

James Januzzi, MD, FACC, FESC
Hutter Family Professor of Medicine, Harvard Medical School; Cardiology Division, Massachusetts General Hospital; Director of Heart Failure and Biomarker Trials, Baim Institute for Clinical Research

Senior Consultant of the National Heart Centre, Singapore; Professor of Duke-National University of Singapore; Co-founder,

12:15 – 1:15 p.m.

4008. Addressing the Risk of Early Recurrent MI: The Evolving Role of HDL in the 90-Day Post-AMI High-Risk Period
Industry-Expert Theater 1, #1957
Sponsored by CSL Behring

Could cholesterol efflux have the potential to reduce the high risk of recurrent CV events in the 90-day window following an AMI? Join our expert faculty of Dr. Eliot Brinton and Dr. Nihar Desai for discussion on the potential link between cholesterol efflux and the clinical importance of the high‑risk 90-day period following an AMI. The session will highlight risk of early recurrence of cardiovascular events despite advances in SOC, as well as explore current understanding of cholesterol efflux to potentially improve CV outcomes. We look forward to welcoming you to a lively, informative and interactive discussion.

Eliot Brinton, MD
President Utah Lipid Center, USA

Nihar Desai, MD, MPH
Associate Professor, Yale School of Medicine,
Associate Chief of the Section of Cardiovascular Medicine, Yale New Haven Health System, USA

4016. Time For CHANGE: Rethinking Rhythm Control to Improve Outcomes in AF
Industry-Expert Theater 2, #2455
Sponsored by Sanofi

Now recognized as a chronic disease requiring an integrated, life-long management strategy, timely restoration and maintenance of sinus rhythm in atrial fibrillation (AF) is emerging as a key component in improving outcomes. Clinical trial data and real-world studies strengthen a growing body of evidence that suggests early rhythm control is associated with improved cardiovascular outcomes, better quality of life, and reduced hospitalization. Join our distinguished panel of experts as they discuss the latest data, updated guideline recommendations, and how new trials are addressing the question of early rhythm control and first-detected AF.

Pam Taub, MD, FACC, FASPC (Chair)
Director of Step Family Foundation
Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System Division of Cardiovascular Medicine
San Diego, California

Jonathan Piccini, MD, MHS, FHRS
Associate Professor of Medicine
Director, Cardiac Electrophysiology
Duke University
Durham, North Carolina

Jagmeet P. Singh, MD, ScM, DPhil
Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts

Information current as of January 4, 2023.

Industry-Expert Theater presentations are not part of ACC.23/WCC, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

American College of Cardiology

© 2022 American College of Cardiology Foundation. Visit

Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us